Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a short video change how families view genetic medicine tests?

NCT ID NCT05037305

Knowledge-focused Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at what children with long-term health conditions and pregnant women know and think about pharmacogenetic testing—a type of genetic test that helps doctors choose the right medicines. About 500 participants will take surveys before and after getting their test results, and some will watch an educational video to see if it improves their understanding. The goal is to learn how to better support these groups in using genetic information for safer, more effective treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

798 people

The number who actually took part.

Started

Jun 2022

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Maternal Inclusion Criteria: * Provide consent in English or Spanish * Primary care at VUMC * Adult women aged 18 and older * Currently pregnant 12 to 30 weeks gestational age * Completed or scheduled first prenatal visit at VUMC clinic * Intent to deliver at VUMC or affiliate * Agrees to receive findings from pharmacogenomic testing * Allow access their medical record Exclusion Criteria: * Stem cell or solid organ transplant * Recent transfusion within the previous 2 months * Inability to provide DNA sample for testing * Prior pharmacogenomic testing * Pregnant women undergoing in vitro fertilization or assisted reproductive technologies Pediatric Inclusion Criteria: * Provide consent (parent/guardian) and/or assent (child) in English or Spanish * Primary care or subspecialty care at VUMC * Aged 0 to 16 * Parent (0-16 years) and child (12-16 years) agree for both parent and child to receive findings from pharmacogenomic testing * Parent (0-16 years) and child (12-16 years) allow access their medical record * Have a chronic health condition. Exclusion: * Stem cell or solid organ transplant * Recent transfusion within the previous 2 months * Inability to provide DNA sample for testing * Prior pharmacogenomic testing

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pharmacogenomic testing are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pharmacogenomic testing

Contacts and locations

Locations

  • Monroe Carell Jr. Children's Hospital at Vanderbilt

    Nashville, Tennessee, 37232, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.